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edge NI after SES.
Methods: Eight month follow-up volumetric IVUS analyses were performed in 35 patients
treated with single SES. Patients were categorized in the edge group when average NI
area, located 1mm inside the stent from either edge, was greater than average NI area of
the non-edge segment. The impact of procedural aggressiveness was evaluated by
assessment of procedural demographics including maximum pressure, balloon:artery
ratio and the previously described artery injury index (product of maximum pressure and
balloon:artery ratio).
Results: Average NI areas, within 1mm from both edges, were 0.67 ± 0.53 and 0.04 ±
0.09 mm2 in the edge and the non-edge group, respectively. Clinical demographics
including age and diabetes mellitus were not different in the two groups. IVUS and proce-
dural data are presented in the Table.
Conclusions: These results suggest that aggressive stent deployment strategy and
smaller vessel size are risk factors for stent edge neointimal formation following siroli-
mus-eluting stent implantation. A less aggressive strategy, particularly in small vessels,
may be important to optimize the long-term durability of this procedure.
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Background: The significant anti-proliferative effect of drug-eluting stents will ncourage
the use of longer stents to treat diffuse coronary lesions as well as to ensure the full cov-
erage of diseased segment. This strategy, however, potentially leads to chronic stent
edge injury by straightening effect of rigid metal stents. The aim of this study was to
investigate the possible association between vessel bending at stent edges and peri-
stent plaque proliferation following bare metal stenting.
Methods: Serial (baseline and 6 months) angiographic and 3D IVUS images were
obtained in 24 cases treated with an identical bare metal stent (3.0-3.5 mm, 18 mm
length). By quantitative angiography at baseline, vessel bending at the stent edge
(defined as the angle between the tangents of two adjacent segments 5 mm inside/out-
side the stent edge) was evaluated by two independent observers. Volumetric IVUS anal-
yses were also independently performed to obtain serial changes in plaque volume at the
proximal and distal reference segments within 2 mm outside the stent edges.
Results: Overall, vessel bending was 17±11º and 14±8º at the proximal and distal stent
edges, respectively. At 6 months, plaque volume significantly increased by 0.98±1.4
(proximal) and 1.04±1.08mm3 (distal). Plaque increase at both the proximal and distal
edge significantly correlated with the degree of vessel bending at baseline (r=0.481,
p<0.05 and r=0.482, p<0.05, respectively).
Conclusions: Significant vessel bending due to stent implantation may be associated with
increased plaque proliferation at stent edges. Enhanced stent conformability to minimize
chronic stent edge injury may be important in the era of drug-eluting stents.
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Background: Experimental data have shown reduced neointimal hyperplasia following
implantation of a titanium-nitride-oxide (TiNOX) coated stents. The objective of the
present study was to evaluate safety and efficacy of TiNOX coated stents for treatment of
de novo coronary artery lesions compared with an uncoated, bare metal stent in a ran-
domized, single-blind, multi-center trial.
Methods: Ninety-two patients (lesion diameter 2.5-3.5 mm, lesion length <15 mm) were
randomly assigned to a TiNOX coated (n=45) or bare metal stent (n=47) of identical
design (slotted tube stent: Omega, AMG, Germany). TiNOX coating was performed by
physical vapor deposition in the vacuum chamber. All stents were manually crimped on a
standard balloon catheter after predilation of the lesion. Dual antiplatelet therapy consist-
ing of acetylsalicylic acid (100 mg qd) and clopidogrel (300mg loading dose, followed by
75 mg qd) was administered for 3 months. Clinical follow-up was performed at 1and 6
months. Pre-, post and follow-up angiograms were analyzed by quantitative coronary
angiography (QCA).
Results: Baseline characteristics were similar in the 2 groups. Lesion length (TiNOX:
13.3±4.0 mm, Control: 12.4±3.3 mm, p=ns) and reference vessel diameter (TiNOX:
2.91±0.40 mm, Control: 2.82±0.31 mm, p=ns) were not different. Device success was
100% in both groups. No stent thrombosis was observed in either group. MACE at 30
days was 2% (1 non-target lesion revascularization) in the TiNOX group and 0% in the
control group (ns). QCA showed a significant reduction in late loss (TiNOX: 0.59±0.64,
Control: 0.94±0.74, p=0.03). Binary restenosis was 15.8% in the TiNOX and 34.1% in the
control group (p=0.06). Target lesion revascularization (TiNOX: 9.1, Control: 27%;
p=0.03) and MACE (TiNOX: 9.1%, Control: 31.1%; p=0.01) at 6 months were significantly
lower in the TiNOX than control group.
Conclusions: Coronary revascularization with TiNOX coated stents is feasible and safe
in patients with de novo coronary artery lesions. TiNOX coated stents significantly reduce
late loss and thus restenosis. TiNOX coated stents were associated with significantly
fewer MACE mainly driven by a decreased need for target lesion revascularization.
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Background: ABT-578, a sirolimus analogue, is a new anti-proliferative agent with prom-
ising preclinical study results. ENDEAVOR I is a multicenter, single-arm trial of the ABT-
578 eluting phosphorylcholine (PC)-coated cobalt-chromium alloy Driver® (Medtronic
Vascular, Santa Rosa, CA) stent in de novo human coronary lesions. The aim of this sub-
study was to evaluate short-term safety of this new drug-eluting stent and its impact on
neointimal proliferation using IVUS.
Methods: IVUS analysis (baseline and 4-month follow-up) was available in 95 out of 100
patients. Seven patients had two stents placed. All stents were 18 mm long and 3.0 / 3.5
mm in diameter.
Results: At baseline, no major plaque protrusion or thrombus was detected over the
stented segment. At 4 months, no late incomplete stent apposition was observed. No sig-
nificant change in minimum luminal area within stented segments was observed between
baseline and 4-month follow-up (6.23 ± 1.51 vs. 6.02 ± 1.71 mm2, NS). Volumetric IVUS
analysis showed that neointimal volume index (neointimal volume / stent length) was
0.32 ± 0.39 mm3/mm (Figure) and percent neointimal volume (neointimal volume * 100 /
stent volume) was 4.5 ± 5.9 %.
Conclusion: Early results of the initial human experience with the ABT-578 eluting PC-
coated stent showed a minimum amount of neointimal proliferation with no apparent
adverse vessel response in the stented segment. Further studies will be warranted to
confirm these favorable observations. 
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Background: FUTURE I is a prospective, randomized trial to evaluate safety and effi-
cacy of everolimus-eluting stents (EES), coated with a unique bioabsorbable polymer,
compared to conventional metallic stents (MS) in the treatment of de novo coronary
lesions. The purpose of this IVUS substudy was to investigate the long-term antiprolifera-
tive effectiveness of EES compared to MS.
Methods and Results: A total of 36 patients completed the angiographic follow-up at 6
months. To date, IVUS images are available in 35 patients (EES 24; MS 11) at 6 months
and 6 patients (all EES) at 12 months. At baseline, EES achieved stent expansion similar
to MS. No significant differences were observed between groups for minimum stent area
(EES 7.0 ± 2.2 vs. MS 6.4 ± 1.2 mm2; P=NS). However, at 6 months follow-up, minimum
lumen area was significantly larger in EES than in MS (EES 6.9 ± 2.6 vs. MS 4.6 ± 1.5
mm2; P<0.01). EES showed 87% volume reduction in neointimal formation compared to
MS (See figure). There was no significant difference in vessel volume post procedure, or
at 6 months follow-up between groups. In 6 patients, neointimal hyperplasia was still sig-
nificantly suppressed at 12 months follow-up. Qualitative analysis showed no evidence of
unhealed dissections or late stent malapposition in either group.
Conclusion: Everolimus-eluting stents, utilizing a unique bioabsorbable polymer, are
effective in preventing neointimal hyperplasia with no evidence of IVUS-detected adverse
effects. 
Edge NI group (n=15) Non-edge NI group (n=20) P-value
Average lumen area 6.95 ± 1.83 7.51 ± 2.29 0.444
Average vessel area 13.66 ± 3.48 16.36 ± 4.18 0.051
Average stent area 7.22 ± 1.87 7.49 ± 2.27 0.710
Average neointimal area 0.31 ± 0.34 0.04 ± 0.08 0.001
Maximum pressure (atm) 18.13 ± 2.99 15.95 ± 2.91 0.037
Balloon:artery ratio 1.05 ± 0.09 0.99 ± 0.15 0.219
Artery injury index 18.87 ± 2.98 15.95 ± 4.37 0.033
